• Explore /
  • Poster
  • / Pembrolizumab versus placebo as adjuvant therapy in resected high-risk stage II melanoma: Phase 3 KEYNOTE-716 study.

Pembrolizumab versus placebo as adjuvant therapy in resected high-risk stage II melanoma: Phase 3 KEYNOTE-716 study.

Abstract Poster

Authors

null

Matteo S. Carlino

Westmead and Blacktown Hospitals, Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia

Matteo S. Carlino , Paolo Antonio Ascierto , Alexander M. Eggermont , Jeffrey E. Gershenwald , Jean Jacques Grob , Axel Hauschild , John M. Kirkwood , Georgina V. Long , Peter Mohr , Caroline Robert , Merrick I. Ross , Richard A. Scolyer , Vernon K. Sondak , Charles Yoon , Andrew Stewart Poklepovic , Piotr Rutkowski , James R. Anderson , Sama Ahsan , Nageatte Ibrahim , Jason J. Luke

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT03553836

Citation

J Clin Oncol 37, 2019 (suppl; abstr TPS9596)

DOI

10.1200/JCO.2019.37.15_suppl.TPS9596

Abstract #

TPS9596

Poster Bd #

166a

Abstract Disclosures

Similar Posters

Poster

2019 ASCO-SITC Clinical Immuno-Oncology Symposium

Phase III KEYNOTE-716 study: Adjuvant therapy with pembrolizumab versus placebo in resected high-risk stage II melanoma.

Phase III KEYNOTE-716 study: Adjuvant therapy with pembrolizumab versus placebo in resected high-risk stage II melanoma.

First Author: Jason J. Luke

First Author: Timothy J. Panella

First Author: Toon Van Gorp

First Author: Fatima Cardoso